Hudson Thomas J 4
4 · AbbVie Inc. · Filed Feb 22, 2021
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Hudson Thomas J
SVP, R&D and CSO
Transactions
- Award
Common Stock, $0.01 par value
2021-02-18+4,216→ 23,859 total - Award
Option(right to buy)
2021-02-18+37,267→ 37,267 totalExercise: $105.92From: 2022-02-18Exp: 2031-02-17→ Common stock (37,267 underlying) - Award
Common Stock, $0.01 par value
2021-02-18+1,240→ 25,099 total - Award
Common Stock, $0.01 par value
2021-02-18+2,530→ 27,629 total - Award
Common Stock, $0.01 par value
2021-02-18+9,483→ 37,112 total
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.
- [F2]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.
- [F3]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.
- [F4]Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021.
- [F5]Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,423 on February 18, 2022 12,422 on February 18, 2023, and 12,422 on February 18, 2024.